Use of Recombinant Factor VIIA (RFVIIA) in Individuals with Congenital Hemophilia B Complicated by Alloantibody Inhibitors to Factor IX: Analysis of Data Capture from the Hemophilia and Thrombosis Research Society (HTRS) Registry (2004-2008)
Pipe SW, Cooper DL
Hemophilia and Thrombosis Research Society (HTRS) Registry Data to Understand Differences in Recombinant Factor VIIA (RFVIIA) Dosing and Clinical Outcomes for the Treatment of Specific Joint Bleeds in Hemophilia
Valentino LA, Cooper DL
Dosing and Effectiveness of Recombinant FVIIA (RFVIIA) in Surgical and Dental Procedures in Congenital Hemophilia with Inhibitors: The Experience of the Hemophilia and Thrombosis Research Society (HTRS) Registry (2004-2008)
Valentino LA,Cooper DL
The Usefulness of Registry Data for Understanding Treatment Practices and Clinical Outcomes in Hemophilia: The Experience of the Hemophilia and Thrombosis Research Society (HTRS) Registry (2004-2008)
Kessler CM, Gill JC, Cooper DL
The Efficacy and Safety of Recombinant Factor VIIA (RFVIIA) in Adult Patients: The Experience of the Hemophilia and Thrombosis Research Society (HTRS) Registry (2004-2008)
Kessler CM, Cooper DL, Carr ME
Safety of Higher Doses of Recombinant Factor VIIA (RFVIIA) ≥250 mcg/kg in Patients with Congenital Hemophilia Complicated by Inhibitors (CHWI): The Hemophilia and Thrombosis Research Society (HTRS) Registry Experience (2004-2008)
Neufeld EJ, Kessler CM, Gill JC, Wilke CT, Cooper DL
A Phase II Study of the Tolerability and Activity of Weekly Vincristine Sulfate Liposomes Injection (VSLI) in Adults with Philadelphia Chromosome-Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) in Second Relapse or Progressing Following Two Antileukemia
Heffner LT, Damon LE, Larson ML, Schiller G, Stock W, Kantarjian HM, Lu B, Imperiale SM, O'Brien S
Patterns of Bleeding in Congenital Hemophilia Patients with Inhibitors and Very Frequent Bleeding: Analysis from the Hemophilia and Thrombosis Research Society (HTRS) Registry
Neufeld EJ, Cooper DL
Phase II Study of Vincristine Sulfate Liposomes Injection in Patients with Metastatic Uveal Melanoma
Bedikian AY, Sato T, Kim KB, Papadopoulos NE, Hwu W, Homsi J, Davies M, Cheung C, Imperiale SM, Prasad P, Hwu P
Outcome of Primary Tumor in Patients with Synchronous Stage IV Colorectal Cancer Receiving Combination Chemotherapy Without Surgery as Initial Treatment
G A Poultsides, E L Servais, L B Saltz, S Patil, N E Kemeny, J G Guillem, M Weiser, L K Temple, W Wong, and P B Paty
Randomized Phase III Trial of Pixantrone Compared with Other Chemotherapeutic Agents for Third-Line Single-Agent Treatment of Relapsed Aggressive Non-Hodgkin's Lymphoma
R Pettengell, G Narayanan, F H Mendoza, R Digumarti, H Gomez, H Gomez, P Cernohous, and I Gorbatchevsky
A Phase III Study of VMPT versus VMP in Newly Diagnosed Elderly Myeloma Patients
A P Palumbo, S Bringhen, D Rossi, S Berretta, V Montefusco, J Peccatori, M Galli, A Carella, P Omedè, M Boccadoro, Italian Multiple Myeloma Network (GIMEMA)
Association Between Immune-Related Adverse Events (irAEs) and Disease Control or Overall Survival in Patients with Advanced Melanoma Treated with 10 mg/kg Ipilimumab in Three Phase II Clinical Trials
J Lutzky, J Wolchok, O Hamid, C Lebbe, H Pehamberger, G Linette, V de Pril, R Ibrahim, A Hoos, and S O'Day
Vandetanib plus Docetaxel versus Docetaxel as Second-Line Treatment for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A Randomized, Double-Blind Phase III Trial (ZODIAC)
R S Herbst, Y Sun, S Korfee, P Germonpré, N Saijo, C Zhou, J Wang, P Langmuir, S J Kennedy, and B E Johnson
Risk of Breast Cancer Recurrence in Women Initiating Tamoxifen with CYP2D6 Inhibitors
R E Aubert, E J Stanek, J Yao, J R Teagarden, M Subar, R S Epstein, T C Skaar, Z Desta, and D A Flockhart
The Antiplatelet Effect of a New, Direct Acting, Reversible P2Y12 Inhibitor, Elinogrel (PRT060128) in Patients with High Platelet Reactivity During Clopidogrel Therapy
P. A. Gurbel, K. Bliden, M. Antonino, P. Andre, G. Stephens, D. Gretler, M. Jurek, A. Hutchaleelaha, A. Singla, T. Suarez, P. Conely, and U. Tantry
A Functional Pool of P2Y12 Receptors Exposed Upon Platelet Activation Persists in Mice Treated with High Dose Clopidogrel, and Can Be Blocked by Elinogrel, a Direct Acting Reversible P2Y12 Inhibitor
H. Haberstock-Debic, P. Andre, S. M. Delaney, S. Mills, Y. Pak, D. R. Phillips, and P. B. Conley
ADP-Mediated Aggregation as a Pharmacodynamic Assay Underestimates the Antithrombotic Activity of Elinogrel, a Competitive, Reversible P2Y12 Inhibitor, Relative to Clopidogrel
P. B. Conley, P. Andre, G. Stephens, H. Haberstock-Debic, M. Jurek, D. Gretler, and D. R. Phillips
Efficacy and Safety of Recombinant Activated Factor VII in the Management of Hemorrhagic Shock Due to Trauma
C. J. Hauser, K. D. Boffard, R. P. Dutton, G. R. Bernar, M. A. Croce, J. B. Holcomb, A. K. Leppaniemi, M. J. A. Parr, J. L. Vincent, B. J. Tortella, J. Dimsits, and B. Bouillon, for the CONTROL Study Group
Clopidogrel and Prasugrel Prolong Primary Hemostasis in the Mouse Beyond Levels Associated with P2Y12 Inhibition
P. Andre, F. DeGuzman, S. Mills, Y. Pak, M. Inagaki, A. Pandey, S. Hollenbach, D. Phillips, and P. Conley
Appropriate VTE Prophylaxis, Compared with Partial VTE Prophylaxis, Leads to Lower VTE Recurrence and Cost in US Medical Patients
A. N. Amin, M. Hussein, D. Battleman, J. Lin, S. Stemkowski, and G. J. Merli
Multiple SNP Testing to predict risk of First Venous Thrombosis
ID Bezemer, CJM Doggen, S le Cessie, PH Reitsma, LA Bare, FR Rosendaal
Long Term (10 Year) Results from the Canadian Hemophilia Primary Prophylaxis Study
V. S. Blanchette, P. Babyn, A. Chan, R. Card, C. Demers, K. Gill, S. Israels, R. Klaassen, N. Laferriere, D. Lillicrap, K. Luke, M. McLimont, M. Pai, M. C. Poon, V. Price, G. E. Rivard, S. Robinson, M. Steele, J. K. M. Wu, and B. M. Feldman
A Predictive Model for Scoring Venous Thromboembolism Risk Factors in Hospitalized Medical Patients: Findings from the IMPROVE Registry
Alex C. Spyropoulos, F. Anderson, G. FitzGerald, H. Decousus, and V. Tapson, for the IMPROVE Investigators
Extended Prophylaxis With Bemiparin for the Prevention Of Late Venous Thromboembolism After Abdominal or Pelvic Surgery for Cancer: A Double-Blind, Randomised, Placebo-Controlled Trial
Vijay V Kakkar, Jose L Balibrea, Javier Martinez-González, Paolo Prandoni on behalf of the CANBESURE Study Investigators
Results of the Second Apixaban Dosed orally Versus ANtiCoagulation with Enoxaparin Study: A randomized double-blind trial comparing apixaban with enoxaparin for thromboprophylaxis after total knee replacement
Michael Rud Lassen, Alex Gallus, Graham Pineo, and Gary Raskob, for the ADVANCE-2 Investigators
Neoadjuvant Chemoradiation is Associated with Improved Survival in Resectable Gastric Cancer
Bose D, et al.
The Effect Of Previous Hormone Replacement Therapy on Post-Menopausal Symptoms in Hormone Receptor-Positive Breast Cancer Patients Treated with Anti-Estrogen Therapy
Chagpar AB; McMasters KM; Lewis J; and Edwards MJ
Does Adjuvant Chemoradiation Treatment Improve Survival in Patients Treated With Gastrectomy and D2-Lymphadenectomy for Gastric Cancer?
Coimbra FJ; Montagnini AL; Diniz AL; Ribeiro HS; Costa Jr, WL; Herman P; and Perini MV
Conservative Management of Breast Cancer in BRCA1/2 Mutation Carriers
Garcia-Etienne CA; Barile M; Gentilini OD; Botteri E; Rotmensz N; Farante G; Luini A; and Bonanni B
Pancreaticojejunostomy (PJ) with a Very Low Rate of Anastomotic Failure Related Complications: A Novel Technique
Grobmyer S; Kooby DA; Cance WG; Blumgart LH; and Hochwald SN
Mortality in the Elderly After Surgical Breast Cancer Therapy: Does Age Worsen Survival?
Kaur P, et al.
Positive Bone Marrow Biopsy is Associated with a Decreased Event Free Survival in Patients with Breast Cancer
Mascaro A; Vitelli CE; Baldi A; Farina M; Amini M; Piro F; and Fortunato L
Mastectomy Offers Improved Overall Survival Over Breast Conservation in Patients Presenting with Metastatic Breast Cancer
McGuire KP; Rodriguez A; Eisen S; Meade T; Cox CE; and Khakpour N
Regional Therapy for Recurrent Metastatic Melanoma Confined to the Extremity: Hyperthermic Isolated Limb Perfusion vs. Isolated Limb Infusion
Reintgen DS; Pendas S; Jakub J; Chan H; Nobo C; Puleo C; and Shivers S
The Value of FDG-PET for Hepatic Surgery of Colorectal Liver Metastases: A Multicentre Randomized Clinical Study
Ruers T, et al.
The Prognostic Significance of Tumor Surgery in Patients with Primary Metastatic Breast Cancer
Ruiterkamp J; Voogd AC; Smilde T; Bosscha K; and Ernst MF
Survival Benefits After Sentinel Lymph Node Mapping in Colon Cancer as Compared to Conventional Surgery
Saha S, et al.
Does Chemotherapy or Radiotherapy Improve Outcomes for Surgically Resected Adenocarcinoma of the Stomach or Esophagus?
Solomon NL; Cheung MC; Byrne MM; and Koniaris LG
Optimizing Multimodality Therapy for Pancreatic Adenocarcinoma
Stitzenberg KB; Watson JC; and Hoffman JP
Outcome Following Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer
Stokes JB, et al.
Analysis of Impact of Short Course Pre-Operative Radiotherapy on Local Relapse and Survival Outcomes in Patients Following Abdominoperineal Excision for Rectal Adenocarcinoma
Tayyab M; Cowley J; Garimella V; Gunn J; MacDonald AW; Hartley JE; and Monson JR
Optimizing Regional Melanoma Therapy: Systemic Sorafenib, an Inhibitor of the B-raf Kinase, Augments the Effectiveness of Concurrently Administered Regional Melphalan Chemotherapy in an Animal Model of Advanced Extremity Melanoma
Toshimitsu H; Augustin C; Padussis JC; and Tyler DS
Long Term Survival Results of Surgery Alone verses Surgery plus 5-Fluorouracil and Leucovorin for Stage II and Stage III Colon Cancer
Wilkinson NW; Yothers G; Lopa SH; Costantino J; Petrelli N; and Wolmark N
Validation Study of the S-Classification for Melanoma in Positive Sentinel Nodes
Younan RJ, et al.
Final Report of a Randomized Phase II Study of Docetaxel/Oxaliplatin (DO) and Docetaxel (D) in Previously Treated Non-Small Cell Lung Cancer (NSCLC) Patients: An Alpe-Adria Thoracic Oncology Multidisciplinary Group Study (Atom 019)
Ornella Belvedere, et al.
Sequential Chemoradiation and Radiation Alone in the Treatment of Inoperable, Locally Advanced Non-Small Cell Lung Cancer (NSCLC) and Sequential Chemoradiation and Radiation Alone in the Treatment of Inoperable, Locally Advanced Non-Small Cell Lung Cancer
Reena Davda, et al.
Outcomes of Small Cell Lung Cancer (SCLC) Patients Treated With Second-Line Chemotherapy (SL): A Retrospective Analysis of 166 Patients
Marina C. Garassino, et al.
A Phase II Study of Weekly Paclitaxel Plus Gemcitabine as Second-Line Therapy in Patients With Metastatic or Recurrent Small Cell Lung Cancer (SCLC)
Heung Tae Kim, et al.
Erlotinib Related Toxicity in Elderly Patients Affected by Non-Small-Cell Lung Cancer (NSCLC)
A. Palazzo et al.
Lapatinib With Chemotherapy in First-Line Treatment of Advanced NSCLC in Never Smokers or Seldom Smokers
R. Pandey, S. Dey, and A. Mukhopadhyay
Slide Decks from 2008 ASH Annual Meeting
December 6-9, 2008 - San Francisco, CA
Maintenance Therapy with Low-Dose Azacitidine (AZA) after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Relapsed or Refractory AML or MDS: A Dose and Schedule Finding Study
De Lima M, de Padua Silva L, Giralt S, Komanduri K, et al.
A Phase 2 Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma. A California Consortium Study
Kirschbaum M, Popplewell L, Nademanee AP, et. al.
Randomized, Double-Blind, Multi-Dose Efficacy, Safety and Biomarker Study of the Oral Factor Xa Inhibitor DU-176b Compared with Placebo for Prevention of Venous Thromboembolism in Patients after Total Knee Arthroplasty
Fuji T, Fujita S, Tachibana S, Kawai Y
Efficacy and Safety Profile of Dabigatran Etexilate Compared with Enoxaparin in Primary Venous Thromboembolism Prevention after Total Knee or Hip Replacement Surgery in Patients Over 75 Years
Dahl OE, Kurth AA, Rosencher N, et. al.
Final Results From A Phase I Combination Study of Lenalidomide and Azacitidine in Patients with Higher-risk Myelodysplastic Syndromes
Sekeres MA, List AF, Cuthbertson D, Paquette R, et al.
Safe Treatment of Pulmonary Embolism on An Outpatient Basis
Kovacs MJ, Hawel JDE, Rekman JF, Lazo-Langner A
Sustained and Prolonged Asparagine Depletion by Multiple Doses of Intravenous Pegylated Asparaginase in the Treatment of Adults with Newly Diagnosed Acute Lymphoblastic Leukemia
Douer D, Watkins K, Mark L, Mohrbacher A, et al.
A Pooled Analysis of Four Pivotal Studies of Rivaroxaban for the Prevention of Venous Thromboembolism after Orthopaedic Surgery: Effect on Symptomatic Venous Thromboembolism, Death, and Bleeding
Turpie AGG, Bauer KA, Davidson BA, Gent M, et al.
Once-Daily Oral Rivaroxaban Compared with Subcutaneous Enoxaparin Every 12 Hours for Thromboprophylaxis after Total Knee Replacement: RECORD4
Turpie AGG, Bauer KA, Davidson BA, Gent M, et al.
Venous Thromboembolism Risk in Stroke Patients Receiving Extended-Duration Enoxaparin Prophylaxis: Sub-Analysis of the EXCLAIM Study
Turpie AGG, Hull RD, Schellong SM, Tapson VF, et al.
Are Hospitals Following Guidelines for VTE Prevention? The Venous Thromboembolism Study to Assess the Rate of Thromboprophylaxis
Amin A, Spyropoulos A, Dobesh P, Shorr A, et al.
Systemic Therapy Utilization Patterns among US Dermatologists and Oncologists Treating Cutaneous T-Cell Lymphoma
Pinter-Brown L, Wisniewski T, Katic B, et al.
Specific Inhibition of Syk Is Sufficient to Disrupt Proliferation and Survival of Non-Hodgkin’s Lymphoma Cell Lines without Concomitant Inhibition of JAK
Coffey G, Luan P, Delaney S, Pandey A, et al.
Specific Pharmacological Targeting of Syk Kinase Activity in Platelets: A Novel, Safe Anti-Thrombotic Strategy
Delaney S, Sim D, Abe K, Nanda N, Siu G, et al.
Incidence of Cancer-Associated Venous Thromboembolism (VTE): A Population-Based Cohort Study
Ashrani AA, Heit JA, Crusan DJ, Petterson TM, et al.
The Effects of Continued Azacitidine (AZA) Treatment Cycles on Response in Higher-Risk Patients (Pts) with Myelodysplastic Syndromes (MDS)
Silverman LR, Verma A, Odchimar-Reissig R, et al.
A Phase I Trial of the Epigenetic Modulators Vorinostat, in Combination with Azacitidine (azaC) in Patients with the Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML): A Study of the New York Cancer Consortium
Silverman LR, Verma A, Odchimar-Reissig R, et al.
Gemtuzumab Ozogamicin (GO) and Continuous Infusion Cytarabine (ARA-C) for Relapsed/Refractory Acute Myeloid Leukemia (AML) Prior to Allogeneic Stem Cell Transplantation (SCT)
Zeidan A, Tan W, Wilding G, Ford L, Hahn T, et al.
Slide Decks from 2007 ISTH Annual Meeting
July 6-12, 2007 - Geneva, Switzerland
Dose Escalating Safety Study of a New Oral Direct Thrombin Inhibitor, Dabigatran Etexilate, in Patients Undergoing Total Hip Replacement: BISTRO I
Eriksson BI, Dahl OE, Ahnfelt L, et al.
A New Oral Direct Thrombin Inhibitor, Dabigatran Etexilate, Compared With Enoxaparin for Prevention of Thromboembolic Events Following Total Hip or Knee Replacement: The BISTRO II Randomized Trial
Eriksson BI, Dahl OE, Buller HR, et al.
The Oral Direct Thrombin Inhibitor, Dabigatran Etexilate, is Effective and Safe for Prevention of Major Venous Thromboembolism Following Major Orthopedic Surgery
Caprini JA, Hwang E, Hantel S, Schnee J, Eriksson B
The Oral Direct Thrombin Inhibitor, Dabigatran Etexilate, is Effective and Safe for Prevention of Major Venous Thromboembolism Following Major Orthopedic Surgery
Caprini JA, Hwang E, Hantel S, Schnee J, Eriksson B
Dabigatran Etexilate Versus Enoxaparin in Preventing Venous Thromboembolism Following Total Knee Arthroplasty
Friedman RJ, Caprini JA, Comp PC, et al.
Late Breaking Clinical Trial - A Dose Finding Study Of The Oral Direct Factor Xa Inhibitor Apixaban in the Treatment of Patients with Acute Symptomatic Deep Vein Thrombosis: The Botticelli Investigators
Buller HR
Rivaroxaban: An Oral, Direct Factor Xa Inhibitor for the Prevention of Venous Thromboembolism in Patients After Total Knee Replacement: A Phase II Dose-Ranging Study
Turpie AG, Fisher WD, Bauer KA, et al.
Oral, Direct Factor Xa Inhibition with Rivaroxaban for the Prevention of Venous Thromboembolism After Total Hip Replacement
Eriksson BI, Borris L, Dahl OE, et al.
Rivaroxaban: An Oral, Direct Factor Xa Inhibitor for the Prevention of Venous Thromboembolism in Total Knee Replacement Surgery – Results of the RECORD 3 Study
Lassen MR,Turpie AG,Rosencher N, et al.
Treatment of Proximal Deep Vein Thrombosis (DVT): Rivaroxaban Once or Twice Daily Had Similar Efficacy and Safety to Standard Therapy in Phase II Studies
Pharmacokinetics (PK) and Pharmacodynamics (PD) of Rivaroxaban: A Comparison of Once- and Twice-daily Dosing in Patients Undergoing Total Hip Replacement (THR)
Eriksson BI,Misselwitz F,Mueck F, et al.
Potential of the Factor Xa Inhibitor Rivaroxaban for the Anticoagulation Management of Patients with Heparin-Induced Thrombocytopenia
J. M. Walenga, W. P. Jeske, M. Prechel, et al.